Patents Issued in February 21, 2019
  • THERAPEUTIC AGENT FOR AMYOTROPHIC DISORDERS
    Publication number: 20190054066
    Abstract: It is an object of the present invention to provide a novel therapeutic agent and method for treating amyotrophic diseases, and more specifically a therapeutic agent and method for treating neurogenic amyotrophic disorders such as amyotrophic lateral sclerosis (ALS) and myogenic amyotrophic disorders such as sarcopenia or disuse muscle atrophy. Provided is a therapeutic agent for amyotrophic diseases that comprises one or more compounds selected from the group consisting of compounds represented by the formula (I), the formula (II) and the formula (III), and pharmaceutically acceptable salts of the compounds when R3 represents OH.
    Type: Application
    Filed: June 24, 2016
    Publication date: February 21, 2019
    Inventors: Takaaki ABE, Masakuni HORIGUCHI, Yuji MATSUMOTO, Maiko NAGAYASU, Keiichi MURAKAMI
  • COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE-LIKE BEHAVIOR IN A SUBJECT
    Publication number: 20190054067
    Abstract: The present invention includes methods of treating obsessive-compulsive disorder and/or an obsessive-compulsive related disorder or disease. The present invention further includes methods of treating symptoms of a compulsive-like behavior, obsessive-compulsive related disorder, and/or compulsive-like behaviors in an autism spectrum disorder or disease. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of a positive allosteric ?4?2 nicotinic acetylcholine receptor modulator, alone or in combination with another positive allosteric ?4?2 nicotinic acetylcholine receptor modulator or an additional agent known to treat the symptoms of obsessive-compulsive disorder, an obsessive-compulsive related disorder, and/or compulsive-like behaviors in autism spectrum disorder or disease.
    Type: Application
    Filed: March 14, 2017
    Publication date: February 21, 2019
    Inventors: MARVIN K. SCHULTE, RICHARD A. GLENNON, ABEL BULT-ITO, SHAILESH KHATRI, SWARUP MITRA
  • Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases
    Publication number: 20190054068
    Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
    Type: Application
    Filed: September 19, 2018
    Publication date: February 21, 2019
    Inventors: Gerard Griffioen, Tom Van Dooren, Veronica Rojas de la Parra, Arnaud Marchand, Sara Allasia, Amuri Kilonda, Patrick Chaltin
  • NEW USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN
    Publication number: 20190054069
    Abstract: The present invention relates to methods and pharmaceutical compositions for treating heart failure in a pediatric human patient comprising administration to said patient of a therapeutically effective amount or a prophylactically effective amount of a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme, in particular of a combination of sacubitril and valsartan in a pharmaceutically acceptable form and in a 1:1 molar ratio.
    Type: Application
    Filed: February 2, 2017
    Publication date: February 21, 2019
    Inventors: Fabian Chen, Surya Prakash Ayalasomayajula, Christopher Bush, Masha Berkhin, Gesine Winzenburg, Bernd Trueby
  • Methods and Compositions for Regenerative Synaptogenesis
    Publication number: 20190054070
    Abstract: Provided herein are uses of pharmaceutically effective amounts of an inhibitor of an arginine methyltransferase alone or in combination with one or more bryostatins to promote regenerative synaptogenesis. Also provided are methods for promoting regenerative synaptogenesis in a patient by administering a pharmaceutically effective amount of an inhibitor of an arginine methyltransferase alone or in combination with a PKC activator to the patient. Likewise, methods are also provided are methods for promoting dendritic maturation in a patient by administering a pharmaceutically effective amount of an inhibitor of an arginine methyltransferase alone or in combination with a PKC activator to the patient, wherein the administration promotes synaptic formation in the hippocampus.
    Type: Application
    Filed: March 16, 2018
    Publication date: February 21, 2019
    Inventor: Daniel L. Alkon
  • SMALL MOLECULE INHIBITORS OF PENDRIN ION EXCHANGE AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20190054071
    Abstract: Provided herein are small molecule inhibitors of pendrin. More specifically, the small molecules disclosed herein may be used to inhibit pendrin-mediated anion exchange. These small molecules may be used for treatment of diseases and disorders that are treatable by inhibiting pendrin, such as cystic fibrosis, rhinitis, chronic rhinosinusitis, exposure to an industrial toxin, certain viral infections, certain bacterial infections, and chronic obstructive pulmonary disease. The small molecules may further be used to potentiate a diuretic effect of a diuretic compound. The small molecules may additionally be used to treat hypertension or thyroid conditions.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 21, 2019
    Inventors: Alan S. VERKMAN, Peter M. HAGGIE, Onur CIL
  • HSP90 TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
    Publication number: 20190054072
    Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
    Type: Application
    Filed: February 23, 2017
    Publication date: February 21, 2019
    Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
  • PHARMACEUTICAL COMPOSITION COMPRISING PYRROLO-FUSED SIX-MEMBERED HETEROCYCLIC COMPOUND
    Publication number: 20190054073
    Abstract: The present invention provides a pharmaceutical composition containing a pyrrolo-fused six-membered heterocyclic compound or a pharmaceutically acceptable salt of the compound. Specifically, the invention provides a pharmaceutical composition containing 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or a pharmaceutically acceptable salt thereof, and at least one water soluble filler. The pharmaceutical composition of the invention features a rapid dissolution and good stability.
    Type: Application
    Filed: February 28, 2017
    Publication date: February 21, 2019
    Inventors: Yun LU, Xinhua ZHANG, Chenyang WANG, Tonghui LIU
  • ANTI-MALARIAL AGENT
    Publication number: 20190054074
    Abstract: The present invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 21, 2019
    Applicant: RIKEN
    Inventors: Akira WADA, Hiroki HAYASE, Nobumoto WATANABE, Hiroyuki OSADA, Takeshi SHIMIZU, Konstanty WIERZBA
  • HYPERBARIC INJECTION SOLUTION OF ROPIVACAINE HYDROCHLORIDE AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20190054075
    Abstract: Disclosed herein is hyperbaric solution for injection of Ropivacaine Hydrochloride which comprises Ropivacaine Hydrochloride; a base/acid to adjust the pH and a baricity adjuster to modify Baricity of the injection solution.
    Type: Application
    Filed: April 1, 2016
    Publication date: February 21, 2019
    Inventors: Neeta JOSHI, Rahul NARKHEDE
  • AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF
    Publication number: 20190054076
    Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 21, 2019
    Applicant: AVALYN PHARMA INC.
    Inventor: Mark William Surber
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING CHLORINE INHALATION TOXICITY AND/OR INJURY
    Publication number: 20190054077
    Abstract: The present invention includes compounds, compositions and methods for treating and/or preventing chlorine inhalation toxicity and/or injury in a subject subjected to chlorine inhalation.
    Type: Application
    Filed: August 17, 2018
    Publication date: February 21, 2019
    Inventor: LIVIA A. VERESS
  • COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS
    Publication number: 20190054078
    Abstract: The invention provides dosage forms and methods utilizing nicotine to treat symptoms of a neurologic disorder. In some embodiments, the invention provides compositions for treatment of gait and balance problems associated with Parkinson's Disease.
    Type: Application
    Filed: July 25, 2017
    Publication date: February 21, 2019
    Inventor: Arasteh Ari AZHIR
  • ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR
    Publication number: 20190054079
    Abstract: During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified in better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week.
    Type: Application
    Filed: March 12, 2018
    Publication date: February 21, 2019
    Inventor: Richard A. Smith
  • ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE
    Publication number: 20190054080
    Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
    Type: Application
    Filed: July 31, 2018
    Publication date: February 21, 2019
    Inventor: Andreas Fischer
  • TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
    Publication number: 20190054081
    Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 21, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Klaus Wening, Anja Geissler-Fichtner, Jana Denker, Lutz Barnscheid
  • METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE
    Publication number: 20190054082
    Abstract: A method for treating brain metastases of a cancer in a mammal includes administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, such as TMZ-POH. The brain metastases can be originated or spread from breast cancer.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 21, 2019
    Inventor: Thomas CHEN
  • METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE
    Publication number: 20190054083
    Abstract: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a ribonucleotide reductase allosteric modulator (RRAmod), the amount being effective to inhibit neoplastic cell growth.
    Type: Application
    Filed: February 13, 2018
    Publication date: February 21, 2019
    Inventor: Chris Dealwis
  • COMBINATION PRODUCTS FOR THE TREATMENT OF RSV
    Publication number: 20190054084
    Abstract: The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl) 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1 cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2 ethyl-sulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2 one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.
    Type: Application
    Filed: February 2, 2017
    Publication date: February 21, 2019
    Inventors: Nina YSEBAERT, Nele Isa E. GOEYVAERTS, Dirk André E. ROYMANS, Anil KOUL
  • COMPOSITION AND METHOD FOR TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS
    Publication number: 20190054085
    Abstract: This application relates to combination compositions for use in treatment of depression, comprising an effective amount of an N-methyl-D-aspartate receptor (NMDAR) antagonist combined with an anti-depressant agent or an atypical antipsychotic approved for treatment of depression. In a preferred embodiment, D-cycloserine is administered at a dose of about 10 mg/kg/d and is formulated to produce sustained blood levels in excess of about 25 microgram/mL.
    Type: Application
    Filed: October 21, 2018
    Publication date: February 21, 2019
    Applicant: Glytech LLC
    Inventor: Daniel C. Javitt
  • PHARMACEUTICAL FORMULATIONS
    Publication number: 20190054086
    Abstract: This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2- yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
    Type: Application
    Filed: March 14, 2018
    Publication date: February 21, 2019
    Inventors: Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
  • TREATMENT OF SMALL CELL LUNG CANCER WITH A PARP INHIBITOR
    Publication number: 20190054087
    Abstract: Described are methods of treatment of a small cell lung cancer subject expressing Schlafen-11 (SLFN 11) with a Poly (ADP-ribose) polymerases (PARP) inhibitor or a pharmaceutically acceptable salt thereof. Specifically, the method comprising detecting SLFN 11 in a tumor cell sample from the subject, and administering effective amount of a PARP inhibitor, such as talazoparib or the tosylate salt of talazoparib, to the subject.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 21, 2019
    Applicant: Medivation Technologies LLC
    Inventors: Ying FENG, Leonard E. POST, Yuqiao SHEN, Yuanbin RU, Evelyn WANG, Karen YU
  • Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
    Publication number: 20190054088
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.
    Type: Application
    Filed: August 20, 2018
    Publication date: February 21, 2019
    Applicants: AbbVie Inc., Neurocrine Biosciences, Inc.
    Inventors: Jayanthy Jayanth, Kevin C. Spence, Gregory A. McClelland, Anna V. Stepanenko, Kristof Chwalisz, Charlotte D. Owens, James W. Thomas, Jane Castelli-Haley, Keith Gordon, Michael C. Snabes, Ahmed M. Soliman, Geoff Zhang, David Metzger, Yanxia Li, Tzuchi R. Ju, Xi Shao, Oscar Antunez Flores, Rita Jain, Juki Wing-Keung Ng, Janine D. North, Hannah Palac, Paul M. Peloso, Laura A. Williams
  • METHODS USED TO TREAT CANCER
    Publication number: 20190054089
    Abstract: The technology encompasses methods of treating a patient with cancer, such as glioblastoma. The methods may include the administration of one or more pharmaceutical compositions that are capable of inhibiting TROY to treat the patient with cancer.
    Type: Application
    Filed: April 8, 2016
    Publication date: February 21, 2019
    Inventors: Nhan Tran, Joseph C. Loftus, Harshil Dhruv
  • COMBINATION OF A BTK INHIBITOR AND A CHECKPOINT INHIBITOR FOR TREATING CANCERS
    Publication number: 20190054090
    Abstract: Provided herein are methods relating to a therapeutic strategy for treatment of cancer, including hematological malignancies. In particular, the methods include administration of a Btk inhibitor and a checkpoint inhibitor, including combinations in which the Btk inhibitor is 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, or a pharmaceutically acceptable salt thereof, and the checkpoint inhibitor is selected from inhibitors of PD-1, PD-L1, and CTLA-4.
    Type: Application
    Filed: September 30, 2016
    Publication date: February 21, 2019
    Inventors: Sriram Venkataraman, Daniel B. Tumas, Kohei Tanaka, Tomoko Yasuhiro, Toshio Yoshizawa
  • PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20190054091
    Abstract: To provide a medicament which shows more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-CLBCL) than the existing Btk inhibitor, and is excellent in safety. The present compound exhibits more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) patients, inter alia, ABC-DLBCL patients having CD79B wild-type gene background than the existing Btk inhibitor, and therefore, it can attain the object of the present invention.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 21, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshio YOSHIZAWA, Ryohei KOZAKI
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING OR AMELIORATING MORTALITY AND/OR MORBIDITY DUE TO CHLORINE INHALATION
    Publication number: 20190054092
    Abstract: The present invention includes compounds, compositions and methods for reducing or ameliorating mortality and/or morbidity due to chlorine inhalation.
    Type: Application
    Filed: August 17, 2018
    Publication date: February 21, 2019
    Inventor: LIVIA A. VERESS
  • TREATMENT OF SARCOPENIA WITH ECDYSTEROIDS
    Publication number: 20190054093
    Abstract: The current disclosure relates to methods for treating loss of muscle mass, by administering compositions comprising a combination of: 20-hydroxy-ecdysone (20HE) or a pharmaceutically acceptable salt thereof; and at least one ecdysteroid selected from the group consisting of polypodine, makisterone A, integristerone, taxisterone, lesterone, rapisterone, inokonesterone, carthamosterone, rubrosterone, leuzeasterone, ayugasterone, turkestrone, salts thereof, and derivatives thereof. The composition optionally further comprises an effective amount of hesperidin.
    Type: Application
    Filed: April 2, 2015
    Publication date: February 21, 2019
    Inventors: Miguel Jimenez del RIO, Jose Maria ZUBEL-DIA FERNANDEZ, Aaron HERNANDEZ SANTANA, Julia Charlotte WIEBE
  • PHARMACEUTICAL COMPOSITION INCLUDING DUTASTERIDE AND CAPSULE FORMULATION COMPRISING THE SAME
    Publication number: 20190054094
    Abstract: The present disclosure relates to a pharmaceutical composition comprising dutasteride and propylene glycol monolaurate, and a capsule formulation comprising the same.
    Type: Application
    Filed: September 9, 2016
    Publication date: February 21, 2019
    Inventors: Taegon BAIK, Seyeon KIM, Kyeongjin AHN, Ju-Hee KIM, Young-joon PARK
  • Aqueous Nebulization Composition
    Publication number: 20190054095
    Abstract: Compositions and methods for making and using stable, homogeneous budesonide compositions are disclosed.
    Type: Application
    Filed: August 14, 2018
    Publication date: February 21, 2019
    Inventor: Ashley Daugherty
  • METHODS FOR ATTENUATING PARASITE VIRULENCE
    Publication number: 20190054096
    Abstract: Pharmaceutical compositions and methods for the treatment of malaria are presented. Such compositions and methods may target energy-sensing pathways of the malaria parasite, Plasmoclium, of parasite host cell, or both. The compositions, in certain aspects of the present invention, target a signalling pathway involving the host AMP-protein activated kinase (AMPK) and/or the parasite AMPK homologue, KIN, which controls parasite replication and virulence.
    Type: Application
    Filed: September 30, 2016
    Publication date: February 21, 2019
    Inventors: Liliana Mancio SILVA, Maria Manuel DIAS DA MOTA
  • COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF
    Publication number: 20190054097
    Abstract: The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the composition comprises a compound of Formula (I) or a compound of Formula (II). The selective killing of senescent cells may delay aging and/or treat age-related disorders.
    Type: Application
    Filed: October 19, 2018
    Publication date: February 21, 2019
    Inventors: Daohong Zhou, Guangrong Zheng, Xuan Zhang, Yingying Wang, Jianhui Chang, Fen Xia, Maria Schuller De Almeida, Ha-Neui Kim, Peiyi Zhang
  • AGENTS AND METHODS USING THEREOF FOR THE PREVENTION AND TREATMENT OF STEM CELLS SENESCENCE
    Publication number: 20190054098
    Abstract: The present invention relates to agents that prevent or reverse process of stem cell senescence. Further, the invention relates to methods and compositions useful in the prevention and/or treatment of stem senescence.
    Type: Application
    Filed: September 7, 2016
    Publication date: February 21, 2019
    Inventors: HONGBO ZHANG, KEIR MENZIES, JOHAN AUWERX, DONGRYEOL RYU
  • NERIDRONIC ACID FOR TREATING COMPLEX REGIONAL PAIN SYNDROME
    Publication number: 20190054099
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 21, 2019
    Inventor: Herriot Tabuteau
  • MEDICAMENT FOR TREATMENT OF DIABETIC FOOT INFECTIONS
    Publication number: 20190054100
    Abstract: The present invention provides means and methods for treating diabetic foot infections. In particular, drug compounds are provided that combine a high therapeutic activity against Staphylococcus Spp. bacteria with a high degree of bone penetration and vasodilatory effects. This unique combination of properties allows to accomplish high local concentrations of the drug at the site of infection even in diabetic foot patients typically having poor blood perfusion at the site of infection.
    Type: Application
    Filed: February 27, 2017
    Publication date: February 21, 2019
    Inventors: Grégoire Vuagniaux, Linda Kadi, Frederick Wittke
  • ARGINASE INHIBITORS AS THERAPEUTICS
    Publication number: 20190054101
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS
    Publication number: 20190054102
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to an anthracycline drug moiety via a disulfide linker, anthracycline disulfide intermediates, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: November 1, 2018
    Publication date: February 21, 2019
    Applicant: Genentech, Inc.
    Inventors: John A. Flygare, Thomas H. Pillow
  • METHOD OF TREATMENT OF TP53 WILD-TYPE TUMORS WITH 2',2'-DIFLUORO-5-AZA-2'-DEOXYCYTIDINE OR PRODRUGS THEREOF
    Publication number: 20190054103
    Abstract: This disclosure provides methods and strategies for inhibiting the growth of TP53 wild-type cancer cells, comprising contacting the cell with 2?,2?-difluoro-5-aza-2?-deoxycytidine or a 2?,2?-difluoro-5-aza-2?-deoxycytidine prodrug. Also provided are related methods for treating a cancer characterized by having wild-type TP53 in a subject in need thereof.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 21, 2019
    Inventor: Richard DAIFUKU
  • PROTON-MOTIVE FORCE STIMULATION TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS AGAINST PERSISTENT BACTERIA
    Publication number: 20190054104
    Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.
    Type: Application
    Filed: August 27, 2018
    Publication date: February 21, 2019
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: James J. Collins, Kyle R. Allison, Mark P. Brynildsen
  • ANTITUMOR ARYLNAPHTHALENE LIGAND GLYCOSIDES
    Publication number: 20190054105
    Abstract: Described are arylnaphthalene lactone derivatives. Also disclosed herein are methods of use of the arylnaphthalene lactone derivatives as anticancer agents.
    Type: Application
    Filed: April 26, 2017
    Publication date: February 21, 2019
    Inventors: James FUCHS, Alan Douglas KINGHORN, Andrew HUNTSMAN
  • FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND THEIR USES
    Publication number: 20190054106
    Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.
    Type: Application
    Filed: August 22, 2018
    Publication date: February 21, 2019
    Inventors: Dov TAMARKIN, Enbal ZIV, Yohan HAZOT, David SCHUZ
  • COMPOSITIONS AND METHODS FOR TREATING AN INFECTION
    Publication number: 20190054107
    Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 21, 2019
    Applicant: CMPD Licensing, LLC
    Inventor: Jay Richard Ray, II
  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    Publication number: 20190054108
    Abstract: Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.
    Type: Application
    Filed: August 20, 2018
    Publication date: February 21, 2019
    Inventors: Lawrence M. Blatt, Leonid Beigelman, Natalia Dyatkina, Julian Alexander Symons, David Bernard Smith
  • An antiviral composition and a method for application thereof
    Publication number: 20190054109
    Abstract: The present invention relates to an antiviral composition and a method for application thereof in the treatment of hepatitis C virus. Said antiviral composition comprises the HCV NS5B inhibitor of general formula 1, or a stereoisomer, an isotopically enriched analog, or crystalline or polycrystalline forms thereof.
    Type: Application
    Filed: April 7, 2017
    Publication date: February 21, 2019
    Inventors: Alexandre Vasilievich Ivachtchenko, Oleg Dmitrievich Mitkin
  • MODULATORS OF CCR9 FOR TREATING TUMOR RESISTANCE TO IMMUNE RESPONSES
    Publication number: 20190054110
    Abstract: The present invention pertains to novel modulators of tumor resistance against T-cell mediated cytotoxic immune responses. The invention provides antagonists of tumor immune escape mechanisms and methods and other aspects related thereto, and therefore provides novel approaches for treating or aiding a treatment of various cancerous diseases and/or the diagnosis thereof. The invention specifically discloses C—C chemokine receptor type 9 (CCR9) as a checkpoint molecule in tumor resistance against cytotoxic T-cells. Provided is the inhibition of CCR9 expression, CCR9 signalling and/or CCR9-T-Cell interaction and inhibitors or antagonists thereof. In particular aspects, the invention provides combination therapeutics and/or therapies involving such inhibitors or antagonists.
    Type: Application
    Filed: February 16, 2017
    Publication date: February 21, 2019
    Inventors: Nisit KHANDELWAL, Philipp BECKHOVE, Michael BOUTROS, Marco BREINIG, Tillmann MICHELS
  • TALEN-BASED GENE CORRECTION
    Publication number: 20190054111
    Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 21, 2019
    Inventors: Mark Osborn, Jakub Tolar, Bruce Robert Blazar, Daniel Voytas
  • POLYNUCLEOTIDE FORMULATIONS FOR USE IN THE TREATMENT OF RENAL DISEASES
    Publication number: 20190054112
    Abstract: The present invention relates to compositions and methods for the preparation, manufacture and therapeutic use of renal polynucleotides.
    Type: Application
    Filed: September 16, 2016
    Publication date: February 21, 2019
    Inventor: Francine M. GREGOIRE
  • METHODS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20190054113
    Abstract: The present disclosure provides, among other things, improved compositions and methods for treating muscular dystrophy. For example, the disclosure provides methods for treating Duchenne muscular dystrophy patients having a mutation in the DMD gene that is amenable to exon 51 skipping by administering an effective amount of eteplirsen.
    Type: Application
    Filed: September 29, 2016
    Publication date: February 21, 2019
    Inventor: Edward M. KAYE
  • EMULSION AND METHOD FOR THE MANUFACTURE THEREOF
    Publication number: 20190054114
    Abstract: The invention relates to an emulsion containing a mixture of an aqueous phase and an oil phase, wherein the aqueous phase comprises seawater, a viscosifier, and a humectant, and wherein the oil phase comprises polyglyceryl, hectorite, propylenecarbonate, t-butyl alcohol, a polyacrylate crosspolymer-6, at least one viscosifier, at least one emulsifier, at least one co-emulsifier, and at least one emollient, such that the phases forming the emulsion are stabilized. Another object of the present invention is the method of manufacture, which allows producing the emulsion with seawater described herein in detail.
    Type: Application
    Filed: January 29, 2018
    Publication date: February 21, 2019
    Applicant: BLUE SEA LABORATORIES, S.L.
    Inventors: Juan Ramón GARCÍA GÓMEZ, Jorge DÍAZ-CRESPO CARDONA
  • COMPOSITIONS AND METHODS FOR INCREASING IRON INTAKE IN A MAMMAL
    Publication number: 20190054115
    Abstract: Compositions containing iron, buffering agent and denatured protein have been prepared that are capable of increasing serum iron in a subject. For example, spray dried microbeads have been prepared containing iron entrapped within a protein matrix and unbound iron in a buffered composition that provides a gastroprotective effect, preserves iron in the more available Fe2+ form and improves iron bioavailability in humans relative to previously known vehicles for delivering iron to a subject.
    Type: Application
    Filed: March 15, 2017
    Publication date: February 21, 2019
    Inventors: John Gilmer, Radics Gabor, Michael Whelehan, Jun Wang, Pat O'Flynn, Mark Ledwidge